Intelligence Platform

Patents

Browse 29,054 pharma-relevant US patents (A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed

patent

US 12054718

RNAi agents for inhibiting expression of PNPLA3, pharmaceutical compositions thereof, and

Arrowhead Pharmaceuticals, Inc. · Granted Tue Aug 06 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12054553

Immunotherapeutic tumor treatment method

Nektar Therapeutics · Granted Tue Aug 06 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12054557

Combination of anti-PD-1 antibodies and bispecific anti-CD20/anti-CD3 antibodies to treat

REGENERON PHARMACEUTICALS, INC. · Granted Tue Aug 06 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12054517

Myeloid differentiation factor 2 (MD2) signaling and modulation

The Regents of the University of California · Granted Tue Aug 06 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12054493

Hepatitis B antiviral agents

Enanta Pharmaceuticals, Inc. · Granted Tue Aug 06 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12054487

Muscarinic acetylcholine M1 receptor antagonists

Contineum Therapeutics, Inc. · Granted Tue Aug 06 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12053531

Materials and methods for treatment of Duchenne Muscular Dystrophy

Vertex Pharmaceuticals Incorporated · Granted Tue Aug 06 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12049670

Proprotein convertase subtilisin/kexin type 1 (PCSK1) variants and uses thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jul 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12050227

Lipid nanodisc formation by acryloyl-based copolymers

THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue Jul 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12049505

Matrix metalloprotease-cleavable and serine or cysteine protease-cleavable substrates and

CytomX Therapeutics, Inc. · Granted Tue Jul 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12049510

Chimeric antigen receptor

AUTOLUS LIMITED · Granted Tue Jul 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12049486

PAC1 receptor agonists (MAXCAPs) and uses thereof

The United States Government represented by the Department of Veterans Affairs · Granted Tue Jul 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12049489

Anti-VEGF protein compositions and methods for producing the same

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jul 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12049457

Highly purified pharmaceutical grade tasimelteon

VANDA PHARMACEUTICALS INC. · Granted Tue Jul 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12049628

Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventin

Alnylam Pharmaceuticals, Inc. · Granted Tue Jul 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12049642

Corneal endothelial cells with increased cell density and compositions thereof

Astellas Institute for Regenerative Medicine · Granted Tue Jul 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12049464

Compounds for targeted degradation of BRD9

C4 THERAPEUTICS, INC. · Granted Tue Jul 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12049630

Factor XII (F12) iRNA compositions and methods of use thereof

Alnylam Pharmaceuticals, Inc. · Granted Tue Jul 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12049645

Differentiation of pancreatic endocrine cells

Vertex Pharmaceuticals Incorporated · Granted Tue Jul 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12048710

Compositions and methods for modification of biomolecules

The Regents of the University of California · Granted Tue Jul 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12048747

Substituted piperidine Degronimers for Target Protein degradation

C4 THERAPEUTICS, INC. · Granted Tue Jul 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12048748

Spirocyclic degronimers for target protein degradation

C4 THERAPEUTICS, INC. · Granted Tue Jul 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12048749

C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors

Revolution Medicines, Inc. · Granted Tue Jul 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12048317

Astaxanthin-containing condiment and a preparation method therefor

South China University of Technology · Granted Tue Jul 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted